beta 2-Microglobulin

β 2 - 微球蛋白
  • 文章类型: Journal Article
    背景:我们之前的研究表明,β2-微球蛋白(β2M)通过SGK1/Bcl-2信号通路促进ER+/HER2-乳腺癌的生存。然而,β2M在ER-/HER2+乳腺癌中的作用尚未被研究。这里,我们旨在确定β2M在ER-/HER2+乳腺癌中的作用。
    方法:通过免疫共沉淀证实了β2M与HFE之间的相互作用,质谱,酵母双杂交筛选,和他的下拉。在MDA-MB-453细胞中进行β2M或HFE的敲减和过表达,和ERK信号通路随后通过蛋白质印迹分析。使用流式细胞仪检测凋亡细胞。β2M,HFE,通过免疫组织化学检查肿瘤和配对的邻近组织中的p-ERK1/2。
    结果:通过免疫共沉淀和质谱,发现HFE是ER-/HER2乳腺癌细胞MDA-MB-453中β2M的相互作用蛋白。酵母双杂交系统和His下拉实验验证了β2M与HFE直接相互作用。β2M和HFE作为复合物主要位于细胞质中,MDA-MB-453细胞的细胞膜上有一些。除乳腺癌细胞BT474外,内源性β2M还与乳腺癌细胞MDA-MB-453,MDA-MB-231和MCF-7中的HFE直接相互作用。β2M通过与HFE相互作用激活ERK信号通路并诱导MDA-MB-453细胞凋亡。HER2过表达的乳腺癌肿瘤组织中HFE和p-ERK1/2的表达明显高于癌旁正常组织,与细胞实验结果一致。
    结论:β2M在HER2过表达的乳腺癌中直接与HFE相互作用,通过激活ERK信号通路诱导肿瘤细胞凋亡。
    BACKGROUND: Our previous study demonstrated that β2-microglobulin (β2M) promoted ER+/HER2- breast cancer survival via the SGK1/Bcl-2 signaling pathway. However, the role of β2M has not been investigated in ER-/HER2+ breast cancer. Here, we aimed to determine the role of β2M in ER-/HER2+ breast cancer.
    METHODS: The interaction between β2M and HFE was confirmed by co-immunoprecipitation, mass spectrometry, yeast two-hybrid screening, and His pull-down. The knockdown and overexpression of β2M or HFE were performed in MDA-MB-453 cells, and ERK signaling pathway was subsequently analyzed via western blotting. Apoptotic cells were detected using flow cytometer. β2M, HFE, and p-ERK1/2 were examined in tumor and paired adjacent tissues via immunohistochemistry.
    RESULTS: HFE was found to be an interacting protein of β2M in ER-/HER2+ breast cancer cells MDA-MB-453 by co-immunoprecipitation and mass spectrometry. A yeast two-hybrid system and His-pull down experiments verified that β2M directly interacted with HFE. β2M and HFE as a complex were mainly located in the cytoplasm, with some on the cytomembrane of MDA-MB-453 cells. In addition to breast cancer cells BT474, endogenous β2M directly interacted with HFE in breast cancer cells MDA-MB-453, MDA-MB-231, and MCF-7. β2M activated the ERK signaling pathway by interacting with HFE and induced apoptosis of MDA-MB-453 cells. The expression of HFE and p-ERK1/2 showed significantly high levels in HER2-overexpressing breast cancer tumor tissue compared with adjacent normal tissue, consistent with the results obtained from the cell experiments.
    CONCLUSIONS: β2M induced apoptosis of tumor cells via activation of the ERK signal pathway by directly interacting with HFE in HER2-overexpressing breast cancer.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    从基因操纵的多能干细胞中衍生低免疫原性人细胞对于未来的移植医学和过继性免疫疗法具有巨大的希望。破坏多能干细胞中的β-2-微球蛋白(B2M),然后分化为专门的细胞类型是一种有希望的方法来获得低免疫原性细胞。鉴于基于CRISPR/Cas9的基因编辑工具和杆状病毒递送系统的有吸引力的特征,杆状病毒可以提供CRISPR/Cas9组件用于B2M的位点特异性基因编辑。在这里,我们报道了一种杆状病毒CRISPR/Cas9载体系统的开发,用于人细胞中B2M基因座的破坏。在人类胚胎干细胞(hESCs)中进行测试时,成功实现了B2M基因敲除/敲除,导致人白细胞抗原I类在细胞表面表达的稳定下调。然后将源自B2M基因破坏的hESC的成纤维细胞用作与人外周血单核细胞共培养的刺激细胞。如通过敏感的Elispot测定所评估的,这些成纤维细胞触发的同种免疫应答显著降低。B2M阴性hESC在体外和体内保持多能性和分化成三个胚芽谱系的能力。这些发现证明了使用杆状病毒-CRISPR/Cas9系统建立B2M破坏的多能干细胞的可行性。B2M敲低/敲除足以导致低免疫原性条件,从而支持B2M阴性细胞作为同种异体细胞治疗的通用供体细胞的潜在用途。
    Derivation of hypoimmunogenic human cells from genetically manipulated pluripotent stem cells holds great promise for future transplantation medicine and adoptive immunotherapy. Disruption of beta-2-microglobulin (B2M) in pluripotent stem cells followed by differentiation into specialized cell types is a promising approach to derive hypoimmunogenic cells. Given the attractive features of CRISPR/Cas9-based gene editing tool and baculoviral delivery system, baculovirus can deliver CRISPR/Cas9 components for site-specific gene editing of B2M. Herein, we report the development of a baculoviral CRISPR/Cas9 vector system for the B2M locus disruption in human cells. When tested in human embryonic stem cells (hESCs), the B2M gene knockdown/out was successfully achieved, leading to the stable down-regulation of human leukocyte antigen class I expression on the cell surface. Fibroblasts derived from the B2M gene-disrupted hESCs were then used as stimulator cells in the co-cultures with human peripheral blood mononuclear cells. These fibroblasts triggered significantly reduced alloimmune responses as assessed by sensitive Elispot assays. The B2M-negative hESCs maintained the pluripotency and the ability to differentiate into three germ lineages in vitro and in vivo. These findings demonstrated the feasibility of using the baculoviral-CRISPR/Cas9 system to establish B2M-disrupted pluripotent stem cells. B2M knockdown/out sufficiently leads to hypoimmunogenic conditions, thereby supporting the potential use of B2M-negative cells as universal donor cells for allogeneic cell therapy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    许多研究已经将银屑病中的炎症途径与代谢性疾病联系起来,虽然没有特定的标记定义它。β2-微球蛋白(β2M)与银屑病严重程度和合并症的关系值得探讨。
    为了研究血液β2M水平与银屑病严重程度之间的相关性,探讨影响关节炎等银屑病合并症发生的炎症因子,糖尿病,和高血压。
    在12周的队列回顾性研究中分析了97名银屑病患者。
    在PASI≥10的组中观察到血液β2M和ESR水平明显高于PASI<10的组。Pearson相关分析显示,血β2M水平与PASI呈显著正相关。在该模型中发现全身炎症因子为银屑病合并症的危险因素,Logistic回归分析显示血β2M水平是糖尿病和高血压的显著相关危险因素。高敏C反应蛋白(hsCRP)是与关节炎相关的重要危险因素。
    患有严重银屑病的患者倾向于具有较高的血液β2M水平和严重的炎症状态。在全身炎症指标中,血β2M水平影响高血压和糖尿病的风险,和hsCRP影响银屑病患者关节炎的风险。
    UNASSIGNED: Numerous studies have linked the inflammatory pathway in psoriasis and metabolic disease, while no specific marker defined it. It is worth exploring the association of β2-microglobulin (β2M) in psoriasis severity and comorbidities.
    UNASSIGNED: To investigate the correlation between blood β2M level and psoriasis severity, to explore the inflammatory factors influencing the occurrence of psoriasis comorbidities such as arthritis, diabetes, and hypertension.
    UNASSIGNED: Ninety-seven psoriasis patients were analyzed in the cohort retrospective study during 12 weeks.
    UNASSIGNED: Significantly higher levels of blood β2M and ESR were observed in the group that patients\' PASI ≥10 than in the group that PASI <10. Blood β2M level had strong significantly positive correlations with the PASI in Pearson\'s correlation analysis. In the model that systemic inflammatory factors to find psoriasis comorbidity risk factors, logistic regression analysis showed that blood β2M level was the significant risk factor associated with diabetes and hypertension. High-sensitivity C-reactive protein (hsCRP) was the significant risk factor associated with arthritis.
    UNASSIGNED: Patients with a severer psoriasis tended to have higher blood β2M levels and severer inflammatory state. In the systemic inflammation indexes, the level of blood β2M affected the risk of hypertension and diabetes, and hsCRP affected the risk of arthritis in patients with psoriasis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:这项研究的目的是确定导致中枢神经系统(CNS)侵袭的危险因素,并验证中枢神经系统国际预后指数(CNS-IPI)对患有弥漫性大B细胞淋巴瘤(DLBCL)的个体的适用性。
    方法:根据是否存在中枢神经系统入侵,365名患者被分为两组:CNS组和非CNS组。采用单因素和多因素分析对患者的临床资料进行回顾性分析,并比较了存活曲线的差异。本研究中的因变量是是否存在中枢神经系统侵袭,而自变量包括年龄,舞台,结外受累,肾/肾上腺受累,和其他人。统计学方法包括卡方检验和Fisher精确检验进行组间比较,以及二元logistic回归进行多因素分析。采用Cox比例风险模型对相关危险因素进行建模。Kaplan-Meier方法用于生成存活曲线,采用对数秩检验比较存活曲线之间的差异。通过利用受试者工作特征(ROC)曲线确定β-2(β2)-微球蛋白的最佳截止值。所有P值都是双向的,P<0.05被认为具有统计学意义。两者都是SPSS23.0(IBMInc.,Armonk,NY,USA)和RStudio(R软件版本4.0.2,RProjectforStatisticalComputing)软件进行数据处理。结果:CNS-IPI的五个因素与CNS侵袭患者的预后相关。骨受累,白蛋白<40g/L,和P53蛋白(+)是DLBCL患者中枢神经系统侵袭的危险因素。然而,预后因素,如双重打击,睾丸受累,乳房受累,子宫受累,骨髓受累不适用于这些患者。还发现,白蛋白水平降低的DLBCL老年患者更容易受到CNS侵袭。此外,结外多部位受累和β-2(β2)微球蛋白升高是独立的预后因素。除了CNS-IPI中的五个因素外,骨受累,白蛋白水平<40g/L,P53蛋白表达是影响DLBCL患者中枢神经系统浸润预后的危险因素。
    OBJECTIVE: The aim of this study is to identify risk factors contributing to central nervous system (CNS) invasion and to validate the suitability of the Central Nervous System International Prognostic Index (CNS-IPI) for individuals afflicted with diffuse large B-cell lymphoma (DLBCL).
    METHODS: Based on the presence or absence of CNS invasion, 365 patients were stratified into two groups: the CNS group and the non-CNS group. The clinical data of the patients were retrospectively analyzed using univariate and multivariate analysis, and the differences in survival curves were compared. The dependent variable in this study was the presence or absence of CNS invasion, while the independent variables included age, stage, extranodal involvement, renal/adrenal involvement, and others. Statistical methods included the chi-squared test and Fisher\'s exact test for intergroup comparison and binary logistic regression for multi-factor analysis. The related risk factors were modeled using the Cox proportional hazards model. The Kaplan-Meier method was used to generate survival curves, and the log-rank test was used to compare the differences between survival curves. The optimal cutoff value of beta-2 (β2)-microglobulin was determined through the utilization of a receiver operating characteristic (ROC) curve. All P values were bidirectional, and P < 0.05 was considered statistically significant. Both SPSS 23.0 (IBM Inc., Armonk, NY, USA) and RStudio (R software version 4.0.2, R Project for Statistical Computing) software were used for data processing RESULTS: The five factors of the CNS-IPI were related to the prognosis of patients with CNS invasion. Bone involvement, albumin < 40 g/L, and P53 protein (+) were the risk factors for CNS invasion in patients with DLBCL. However, prognostic factors such as double strike, testicular involvement, breast involvement, uterine involvement, and bone marrow involvement did not apply to these patients. It was also discovered that elderly patients with DLBCL with reduced albumin levels were more susceptible to CNS invasion. Furthermore, extranodal involvement at multiple sites and elevated beta-2 (β2) microglobulin were independent prognostic factors CONCLUSION: Patients older than 60 years with DLBCL and decreased albumin are at increased risk for CNS invasion. In addition to the five factors in the CNS-IPI, bone involvement, albumin levels < 40 g/L, and P53 protein expression are risk factors affecting the prognosis of CNS invasion in patients with DLBCL.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    探讨新诊断的多发性骨髓瘤(MM)患者在不同阶段和不同M蛋白类型时凝血功能的变化,并分析凝血指标与β2-微球蛋白(β2-MG)的相关性。
    从2016年1月至2022年12月共选择371例新诊断的MM患者(n=371)和健康对照(n=48)。基线数据,收集β2-MG和凝血指数值。指标包括凝血酶原时间(PT),活化部分凝血活酶时间(APPT),纤维蛋白原(FIB),凝血酶时间(TT),纤维蛋白原降解产物(FDP),和D-二聚体(D-D)。根据Durie-Salmon分期系统(DS)将患者分为不同的组,国际分期系统(ISS)和疾病分类(M蛋白类型)。比较各组间6项指标水平,分析各指标与β2-MG的相关性。
    与正常对照组相比,PT的水平,FIB,TT,MM组FDP和D-D显著增高(均P<0.001)。随着DS和ISS分期的增加,PT的水平,TT,FDP和D-D也显著增加(均P<0.001)。β2-MG与PT呈正相关,TT,和FDP水平(Spearmanr分别为0.157、0.270、0.108;所有P<0.05),与FIB呈负相关(r=-0.220,P<0.001)。6项指标在不同M蛋白类型间存在显著差异(均P<0.001)。其中,IgA-κ组PT和APTT明显升高,FIB在λ轻链基团中增加,IgG-κ组TT升高,FDP在κ轻链基团中增加,IgG-λ组的D-D增加。
    MM患者的凝血功能障碍程度随疾病分期而加重,各种凝血指标的异常升高发生在不同的M蛋白类型中,与β2-MG密切相关。
    UNASSIGNED: To explore the changes in the coagulation function of patients newly diagnosed with multiple myeloma (MM) at different stages and with different M protein types, and to analyze the correlation between coagulation indexes and β2-microglobulin (β2-MG).
    UNASSIGNED: A total of 371 Patients with newly diagnosed MM (n = 371) and healthy controls (n = 48) were selected from January 2016 to December 2022. Baseline data, β2-MG and coagulation index values were collected. Indexes included prothrombin time (PT), activated partial thromboplastin time (APPT), fibrinogen (FIB), thrombin time (TT), fibrinogen degradation products (FDP), and D-dimer(D-D). Patients were divided into different groups according to the Durie-Salmon staging system (DS), the International Staging System (ISS) and disease classification (M protein type). The levels of these six indexes were compared among the groups and the correlation between each index and β2-MG was analyzed.
    UNASSIGNED: Compared to the normal control group, the levels of PT, FIB, TT, FDP and D-D in the MM group were significantly higher (all P < 0.001). As DS and ISS staging increased, the levels of PT, TT, FDP and D-D also increased significantly (all P < 0.001). β2-MG was positively correlated with PT, TT, and FDP levels (Spearman r = 0.157, 0.270, 0.108, respectively; all P < 0.05), and negatively correlated with FIB (r = -0.220, P < 0.001). Significant differences existed in the levels of these six indexes among different M protein types (all P < 0.001). Among them, PT and APTT increased significantly in the IgA-κ group, FIB increased in the λ light chain group, TT increased in the IgG-κ group, FDP increased in the κ light chain group, and D-D increased in the IgG-λ group.
    UNASSIGNED: The degree of coagulation dysfunction in MM patients increases with disease stage and abnormal increases of various coagulation indicators occur in different M protein types and are closely related to β2-MG.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:调查9种尿液生物标志物在2型糖尿病(T2DM)患者中的分布,有或没有微血管并发症。
    方法:总共,从2021年到2022年,有407名T2DM患者注册。根据糖尿病视网膜病变(DR)和尿白蛋白-肌酐比值(UACR),407人分为四(4)组,DR(-)UACR(-),DR(+)UACR(-),DR(-)UACR(+),和DR(+)UACR(+)。此外,同期纳入112名健康志愿者。九(9)个尿液标记包括α1-微球蛋白(u-α1MG),免疫球蛋白G(u-IgG),中性粒细胞明胶酶相关脂质载体蛋白(u-NGAL),胱抑素C(u-CysC),视黄醇结合蛋白(u-RBP),β2-微球蛋白(u-β2MG),N-乙酰-β-D-氨基葡萄糖苷酶(u-NAG),转铁蛋白(u-Trf),和胶原IV型(u-Col)。对于每个标记,健康志愿者各自的97.5百分位数水平作为参考上限.
    结果:在407人中,248例(61%)为DR(-)UACR(-),100(25%)为DR(-)UACR(+),37(9%)为DR(+)UACR(-),DR(+)UACR(+)22例(5%)。u-NAG/Cr生物标志物水平显示健康参与者和T2DM患者之间存在显着差异。在DR(-)UACR(-)组中,u-Trf/Cr阳性率最高(21.37%),其次是u-IgG/Cr(14.52%);u-NAG/Cr(10.48%);u-β2MG/Cr(4.44%);u-CysC/Cr(4.03%);u-NGAL/Cr(4.03%);u-RBP/Cr(2.82%);u-α1MG/Cr(2.42%);17.34%的T2DM患者生物标志物≥2。在T2DM少于五(5)年的人群中,一种生物标志物(21.33%)和两种生物标志物(18.67%)的阳性率几乎接近DR(-)UACR(-)组(21.37%,12.10%,分别)。
    结论:肾小管生物标志物可作为糖尿病肾损伤的早期检测和监测指标。对于初次诊断的T2DM患者,应测量u-NAG生物标志物。
    To investigate the distribution of nine (9) urine biomarkers in people living with type 2 diabetes mellitus (T2DM), with or without microvascular complications.
    In total, 407 people with T2DM were enrolled from 2021 to 2022. According to diabetic retinopathy (DR) and urinary albumin-creatinine ratio (UACR), the 407 people were divided into four (4) groups, DR(-)UACR(-), DR(+)UACR(-), DR(-)UACR(+), and DR( + )UACR(+). In addition, 112 healthy volunteers were enrolled during the same period. The nine (9) urine markers included α1-microglobulin (u-α1MG), immunoglobulin G (u-IgG), neutrophil gelatinase-associated lipid carrier protein (u-NGAL), cystatin C (u-CysC), retinol-binding protein (u-RBP), β2-microglobulin (u-β2MG), N-acetyl-β-D-glucosaminidase (u-NAG), transferrin (u-Trf), and collagen type IV (u-Col). For each marker, the respective level of 97.5 percentile in healthy volunteers was taken as an upper reference limit.
    Among the 407 people, 248 individuals (61%) were DR(-)UACR(-), 100 (25%) were DR(-)UACR(+), 37 (9%) were DR(+)UACR(-), and 22 (5%) were DR(+)UACR(+). The u-NAG/Cr biomarker level showed a significant difference between healthy participants and people with T2DM. In the DR(-)UACR(-)group, u-Trf/Cr showed the highest positive rate (21.37%), followed by u-IgG/Cr (14.52%); u-NAG/Cr (10.48%); u-β2MG/Cr (4.44%); u-CysC/Cr (4.03%); u-NGAL/Cr (4.03%); u-RBP/Cr (2.82%); u-α1MG/Cr (2.42%); 17.34% of people with T2DM showed multiple biomarkers positive (≥2 biomarkers). The positive rates of one biomarker (21.33%) and two biomarkers (18.67%) in people who have less than five (5) years of T2DM were almost close to those of the DR(-)UACR(-) group (21.37%, and 12.10%, respectively).
    Renal tubule biomarkers may be used as an indicator in the early detection and monitoring of renal injury in diabetes mellitus. The u-NAG biomarker should be measured for the people with T2DM of the first-time diagnosis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: English Abstract
    Objective: To explore the correlation of bone marrow polychonal plasma cell proportion (pPC% ) and clinical features in newly diagnosed multiple myeloma (NDMM) patients. Methods: A retrospective analysis of 317 patients with NDMM admitted to Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 2018 to January 2023 was performed. The results of the pPC% in all patients were clear. The relationship between the pPC% and clinical characteristics was analyzed. Results: A total of 317 patients were included, comprising 180 males and 137 females. The median age at diagnosis was 61 (26-91) years, and 55.8% were 60 years or older. The pPC% in the bone marrow of patients with NDMM was different in the DS, International Staging System (ISS), and revised ISS (R-ISS) stages (P=0.002, 0.010, and 0.049, respectively), whereas no statistical difference in pPC% was observed among patients with different FISH risk stratigrams (P=0.971). The correlation coefficient between pPC% and hemoglobin (HGB) at the first diagnosis in patients was 0.211 (P<0.01). The correlation coefficients with serum calcium, serum creatinine, M protein level, and β(2)-microglobulin were -0.141, -0.120, -0.181, and -0.207, respectively, and the results of the significance test were P=0.012, 0.033, 0.004, and 0.002, respectively, indicating a negative correlation. Compared with the patients with a pPC% of ≥2.5%, the group of patients with a pPC% of <2.5% had significantly higher levels of light chain, serum calcium, serum creatinine, M protein, and β(2)-microglobulin at the initial diagnosis (P<0.05) ; lower HGB level (P<0.001) ; and a higher proportion of patients in ISS stage Ⅲ (P=0.034) . Conclusion: In this study, the pPC% in patients with NDMM was associated with clinical features of good prognosis, including higher HGB, lower serum calcium, serum creatinine, M protein quantity, β(2)-microglobulin, light chain involvement, lower proportion of advanced disease (DS stage and ISS stage Ⅲ), and clinical features showing lower tumor burden.
    目的: 探究初诊多发性骨髓瘤(NDMM)患者骨髓多克隆浆细胞占比(pPC%)与临床特征的相关性。 方法: 回顾性分析2018年1月至2023年1月在华中科技大学同济医学院附属同济医院收治的317例NDMM患者,纳入患者均有明确的pPC%结果。分析pPC%与临床特征的关系。 结果: 共纳入317例患者,其中男180例,女137例,中位确诊年龄61(26~91)岁,≥60岁患者占55.8%。NDMM患者骨髓pPC%在各DS分期、ISS分期、R-ISS分期组差异均有统计学意义(P值分别为0.002、0.010、0.049),而不同的FISH危险分层患者pPC%差异无统计学意义(P=0.971)。NDMM患者pPC%与患者初诊时HGB呈正相关(r=0.211,P<0.01);与血钙、血肌酐、单克隆免疫球蛋白(M蛋白)定量、β(2)微球蛋白水平呈负相关(r分别为-0.141、-0.120、-0.181、-0.207,P值为0.012、0.033、0.004、0.002)。与pPC%≥2.5%患者相比,pPC%<2.5%组患者初诊时受累轻链、血钙、血肌酐、M蛋白和β(2)微球蛋白水平明显升高(P值均<0.05),HGB降低(P<0.001),ISS分期Ⅲ期比例更高(P=0.034)。 结论: NDMM患者pPC%与良好预后的临床特征相关,包括更高的HGB,更低的血钙、血肌酐、M蛋白定量、β(2)微球蛋白,受累轻链,更低的晚期疾病占比(DS分期、ISS分期Ⅲ期),在临床特点上表现为肿瘤负荷较小。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: English Abstract
    OBJECTIVE: To investigate the clinical significance of bone metabolic indexes for disease assessment and curative effect monitoring in multiple myeloma (MM) bone disease (MBD) patients with different blood separation results.
    METHODS: A total of 134 newly diagnosed MM patients treated in Cangzhou Hospital of Integrated TCM-WM-Hebei were enrolled and divided into control group [119 cases, serum, colloid and red blood cell (RBC) from top to bottom of sample] and abnormal group (15 cases, serum, mixed layer of RBC and serum, colloid and RBC from top to bottom of sample) according to the results of blood separation. According to the imaging findings, MBD was classified into grade 0-4, grade 0-2 was mild, and grade 3-4 was severe. The MBD grade of patients in the two groups was analyzed. The curative effect of MBD patients after chemotherapy and the changes of blood separation results and bone metabolic indexes before and after treatment were evaluated. The correlation between β2-microglobulin (MG) and bone metabolic indexes was analyzed by Pearson correlation analysis.
    RESULTS: In the control group, there were 69 cases of grade 0-2 and 50 cases of grade 3-4, while in the abnormal group, there were 5 cases of grade 0-2 and 10 cases of grade 3-4, the difference was statistically significant (P < 0.05). The serum β2-MG, β-CTX levels in abnormal group were both significantly higher than those in control group, while the levels of P1NP and osteocalcin (OC) were significantly lower (all P < 0.001). In the control group, there were 95 patients with ≥ partial response (PR) and the blood separation results were not changed, while 24 patients with 0.05). Compared with before treatment, the levels of β-CTX and β2-MG in the control group with unchanged blood separation results were significantly decreased (both P < 0.001), while the levels of P1NP and OC were significantly increased (P < 0.01, P < 0.001), and the level of each index in the patients transformed to abnormal blood separation result after treatment did not significantly change (P >0.05); the levels of β-CTX and β2-MG in the abnormal group transformed to normal blood separation result were significantly decreased (both P < 0.01), while the levels of P1NP and OC were significantly increased (P < 0.001, P < 0.01), and the level of each index in patients with unchanged blood separation results did not significantly change (P>0.05). Pearson correlation analysis showed that serum β2-MG was positively correlated with β-CTX (r =0.709, P < 0.001), and negatively correlated with P1NP and OC (r =-0.410,r =-0.412, both P < 0.001).
    CONCLUSIONS: MBD patients with abnormal blood separation results have higher bone disease grade and poor prognosis, which is closely related to the significant increase of bone resorption index β-CTX level and decrease of bone formation index P1NP and OC levels, leading to more serious bone metabolic homeostasis disorder. The results of blood separation combined with the changes of bone metabolic indexes can be used as one of the comprehensive predictors of disease condition, efficacy monitoring and prognosis evaluation of MBD patients.
    UNASSIGNED: 不同血液分离结果的多发性骨髓瘤骨病患者骨代谢水平研究.
    UNASSIGNED: 探讨不同血液分离结果的骨髓瘤骨病(MBD)患者骨代谢指标对病情评估及疗效监测的临床意义。.
    UNASSIGNED: 纳入2016年3月至2020年3月河北省沧州中西医结合医院收治的134例初诊MM患者,根据血液离心结果,分为对照组119例(样本自上而下依次为血清、胶体、红细胞),异常组15例(样本自上而下依次为血清、红细胞、胶体、红细胞),根据影像学表现将MBD分为0-4级,0-2级为骨病较轻者,3-4级为骨病较重者,分析两组患者MBD的分级情况,并对不同血液分离结果的MBD患者进行疗效评价,分析治疗前后血液分离结果及骨代谢指标水平的变化,采用Pearson相关分析法分析β2-微球蛋白(MG)与骨代谢指标水平的相关性。.
    UNASSIGNED: 对照组0-2级69例,3-4级50例;异常组0-2级5例,3-4级10例,比较差异具有统计学意义(P < 0.05)。异常组血清β2-MG、Ⅰ型胶原羧基端肽β特殊序列(β-CTX)水平显著高于对照组,而Ⅰ型前胶原氨基端前肽(P1NP)、骨钙素(OC)水平显著低于对照组(均P < 0.001)。对照组95例疗效≥部分缓解(PR),其血液分离结果未改变;24例疗效< PR,其中5例血液分离结果转为异常。异常组9例疗效≥PR,血液分离结果均转为正常;6例疗效< PR,其中5例血液分离结果仍为异常。与治疗前相比,对照组疗效≥PR的患者β-CTX、β2-MG水平显著降低,而P1NP、OC水平显著升高(均P < 0.001);异常组疗效≥PR的患者β-CTX、β2-MG水平亦显著降低(P < 0.001,P < 0.01),而P1NP、OC水平显著升高(P < 0.001,P < 0.01)。两组疗效 < PR的患者各指标水平与治疗前相比无明显变化(P >0.05)。与疗前相比,对照组治疗后血液分离结果未改变的患者β-CTX、β2-MG水平显著降低(均P < 0.001),P1NP、OC水平显著升高(P < 0.01,P < 0.001),而血液分离结果转为异常的患者各指标水平无明显变化(P >0.05);异常组治疗后血液分离结果转为正常的患者β-CTX、β2-MG水平显著降低(均P < 0.01),P1NP、OC水平显著升高(P < 0.001,P < 0.01),而血液分离结果未改变的患者各指标水平无明显变化。Pearson相关分析显示,患者血清β2-MG与β-CTX水平呈正相关(r =0.709,P < 0.001),与P1NP、OC水平呈负相关(r =-0.410、-0.412,均P < 0.001)。.
    UNASSIGNED: 存在血液异常分离结果的MBD患者骨病分级较高、预后较差,与骨吸收指标β-CTX水平显著升高,骨形成指标P1NP、OC水平显著降低,引起更严重的骨代谢动态平衡紊乱密切相关。血液分离结果联合骨代谢指标水平的变化可作为MBD患者病情、疗效监测及预后评估的综合预测指标之一。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: English Abstract
    OBJECTIVE: To investigate the relative expression level and clinical significance of LINC00475 in serum of patients with multiple myeloma (MM).
    METHODS: The expression of LINC00475 in serum of 108 MM patients and five MM cell lines including RPMI 8226, NCI-H929, U266, OPM2 and CAG were detected by real-time fluorescence quantitative PCR. The diagnostic value of LINC00475 in MM was evaluated by receiver operating characteristic (ROC) curve analysis. The correlation of LINC00475 with patients\' characteristics was analyzed.
    RESULTS: Compared with control groups, the expression of LINC00475 was up-regulated in serum of MM patients and MM cell lines (all P < 0.05). ROC curve analysis showed that the optimal cut-off value of LINC00475 was 262.4, the area under curve (AUC) was 0.924(95%CI : 0.884-0.964), and sensitivity and specificity was 83.3% and 91.7%, respectively, which indicated that LINC00475 had good evaluation value in MM patients. Compared with low-LINC00475 expression group, patients in high-LINC00475 expression group had higher levels of β2microglobulin (β2-MG) and Cystatin C (Cys-C) but lower albumin (ALB) (all P < 0.05). Compared with MM patients with International Staging System (ISS) stage I, the expression level of LINC00475 was significantly higher in patients with stage II and III (both P < 0.05).
    CONCLUSIONS: LINC00475 is helpful to distinguish MM patients from healthy adults, which is correlated with the prognostic indicators such as β2-MG, ALB, and ISS stage.
    UNASSIGNED: LINC00475在多发性骨髓瘤中的表达与临床意义.
    UNASSIGNED: 探讨LINC00475在多发性骨髓瘤(MM)患者血清中的相对表达水平及临床意义。.
    UNASSIGNED: 用实时荧光定量PCR技术检测108例MM患者血清及RPMI 8226、NCI-H929、U266、OPM2、CAG这5个MM细胞系中LINC00475的表达情况,受试者工作特征曲线评估其对MM的诊断价值,并结合患者的临床资料分析LINC00475与患者临床特征的关系。.
    UNASSIGNED: 与健康对照组相比,MM患者血清及MM细胞系中LINC00475的表达明显上调(均P < 0.05)。受试者工作特征曲线分析显示,LINC00475的最佳截断值为262.4,曲线下面积为0.924(95%CI :0.884-0.964),灵敏度83.3%,特异度91.7%,表明LINC00475在MM患者中具有良好的评估价值。与LINC00475低表达组的MM患者相比,高表达组的患者具有较高水平的β2微球蛋白和胱抑素C(均P < 0.05),但白蛋白水平较低(P < 0.05)。与ISS分期Ⅰ期的MM患者相比,Ⅱ期和Ⅲ期患者LINC00475的表达水平均明显增高(均P < 0.05)。.
    UNASSIGNED: 检测LINC00475的相对表达水平有助于区分MM患者和正常人群,其相对表达水平与MM患者的β2-微球蛋白、白蛋白、ISS分期等预后指标相关。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: English Abstract
    OBJECTIVE: To investigate the role of serum adenosine deaminase (ADA) combined with globulin (GLB), creatinine (CREA), β2-microglobulin (β2-MG) and hemoglobin (HGB) in the initial screening of multiple myeloma (MM), in order to reduce missed diagnosis and misdiagnosis of MM.
    METHODS: A retrospective analysis was performed on 62 newly diagnosed multiple myeloma (NDMM) patients who were admitted to the Department of Hematology of the First Affiliated Hospital of Chengdu Medical College from April 2018 to December 2021, and 33 patients with benign hematologic diseases and 30 healthy subjects were selected as the control group. The expression of ADA in pan-cancer was analyzed using TCGA and GTEx databases. The general data and laboratory indicators of the subjects were collected, and the differences of ADA activity and other laboratory indicators in each group were compared. The relationship between serum ADA activity and clinical data of NDMM patients was analyzed. The changes of ADA activity before and after chemotherapy in NDMM patients and the differences of ADA activity in NDMM patients with different DS and ISS stages were compared. Multivariate logistic regression was used to analyze the risk factors of NDMM. The receiver operating characteristic(ROC) curve was used to evaluate the diagnostic efficacy of ADA and other laboratory indicators in MM. Bioinformatics method was used to analyze the co-expression networks and enrichment pathways of ADA.
    RESULTS: ADA level was significantly upregulated in tissues of 14 types of cancer in TCGA database, and ADA was highly expressed in 11 types of cancer in TCGA combined with GTEx databases. The serum levels of ADA, GLB, uric acid (UA), cystatin C (CysC) and β2-MG in the NDMM group were significantly higher than those in benign hematologic disease group and healthy control group ( P < 0.05), while the levels of ALB and the value of albumin to globulin ratio (A∶G) in the NDMM group were significantly lower than those in the other two groups ( P < 0.001). There were significant differences in DS stage (P =0.036), ISS stage (P =0.019) and the levels of CREA (P =0.036), UA (P =0.034), β2-MG (P =0.019) in NDMM patients with different ADA activity levels. After primary chemotherapy, ADA activity and β2-MG concentration were decreased in NDMM patients ( P < 0.01). The comparison results of patients in different stages showed that ADA activity of patients in DS stage I+II was significantly lower than that of patients in DS stage III (P <0.05), and ADA activity of patiens in ISS stage I+II was significantly lower than that of patients in ISS stage III ( P < 0.01). Multivariate logistic regression analysis showed that increased GLB, increased ADA activity, increased CREA, increased β2-MG and decreased HGB were independent risk factors for NDMM. The area under the curve (AUC) of ADA in the diagnosis of MM was 0.847, and the AUC of ADA combined with GLB, CREA, β2-MG and HGB in the diagnosis of MM was 0.940. The results of co-expression network and enrichment pathway analysis showed that ADA bounded to 20 proteins and it was significantly associated with the metabolic pathways of purine, pyrimidine, nicotinate and nicotinamide.
    CONCLUSIONS: The detection of ADA activity in serum is of positive significance for the auxiliary diagnosis, therapeutic evaluation and monitoring the progress of NDMM patients. ADA combined with GLB, CREA, β2-MG and HGB can improve the detection rate of MM, and reduce missed diagnosis and misdiagnosis to a certain extent.
    UNASSIGNED: 血清ADA联合GLB、CREA、β2-MG、HGB在初诊多发性骨髓瘤中的临床意义.
    UNASSIGNED: 研究血清腺苷脱氨酶(ADA)联合球蛋白(GLB)、肌酐(CREA)、β2-微球蛋白(β2-MG)、血红蛋白(HGB)对多发性骨髓瘤(MM)的初筛作用,减少MM的漏诊及误诊。.
    UNASSIGNED: 回顾性分析2018年4月至2021年12月成都医学院第一附属医院血液科收治的62例初诊多发性骨髓瘤(NDMM)患者的资料,并以33例良性血液病患者和30例健康体检者作为对照组。用TCGA和GTEx数据库分析ADA在泛癌中的表达。收集受试者的一般资料及实验室检测指标,比较各组ADA活性及其他实验室指标水平的差异。分析血清ADA活性与NDMM患者临床资料的关系。比较NDMM患者化疗前后ADA活性的变化以及不同DS、ISS分期NDMM患者中ADA活性的差异。多因素Logistic回归分析NDMM发生的危险因素。采用ROC曲线评价ADA及其联合其他实验室指标对MM的诊断效能。生物信息学分析ADA的共表达网络和富集途径。.
    UNASSIGNED: TCGA 数据库中有14种癌组织中ADA水平显著上调,TCGA联合GTEx 数据库中ADA 在11种癌症中高表达。NDMM组外周血清ADA、GLB、UA、CysC、β2-MG水平明显高于良性血液病组及健康对照组( P < 0.05),ALB、A∶G明显低于良性血液病组及健康对照组( P < 0.001)。不同ADA活性水平的NDMM患者的DS分期(P =0.036)、ISS分期(P =0.019)、CREA(P =0.036)、UA(P =0.034)、β2-MG(P =0.019)水平具有统计学差异。NDMM患者初次化疗后ADA活性及β2MG浓度有所下降( P < 0.01)。不同DS分期和ISS分期患者比较结果显示,DS I+II期患者ADA活性明显低于Ⅲ期患者( P < 0.05),ISS I+II期患者ADA活性也明显低于Ⅲ期患者( P < 0.01)。多因素Logistic回归分析结果显示,GLB增高、ADA活性增加、CREA增高、β2-MG增高、HGB降低是NDMM的独立危险因素。ADA诊断MM的曲线下面积为0.847,其联合GLB、CREA、β2-MG、HGB诊断MM的曲线下面积为0.940。共表达网络和富集途径分析结果显示,ADA与20种蛋白质结合,并与嘌呤代谢、嘧啶代谢、烟酸和烟酰胺代谢通路显著相关。.
    UNASSIGNED: 检测血清中的ADA活性,对MM患者的辅助诊断、疗效评估以及监测疾病的发展有着积极的意义。ADA联合GLB、CREA、β2-MG、HGB可提高MM的初筛检出率,可在一定程度上减少漏诊及误诊。.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号